argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
July 16, 2026 01:00 ET | Source: argenx SE July 16, 2026Amsterdam,…
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and…
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 01:00 ET | Source: argenx SE May 28, 2026Amsterdam,…
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for…
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as…
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026 01:00 ET | Source: argenx SE February 23, 2026Amsterdam,…
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential…
